RECRUITING

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.

Official Title

Pilot Trial of LET Optimized IMPT for Pediatric Patients With Ependymoma

Quick Facts

Study Start:2019-04-01
Study Completion:2027-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03750513

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 22 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
  2. * Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)
  3. * Patient may not receive chemotherapy concurrent with radiation
  4. * Signed informed consent by patient and/or parents or legal guardian
  5. * Lansky performance status score of 50 -100
  1. * Patients with previous radiation therapy to the brain
  2. * Ependymoma of the spine
  3. * Disseminated ependymoma requiring craniospinal radiation therapy
  4. * Pregnancy
  5. * Inability to undergo MR imaging
  6. * Inability to receive gadolinium-based contrast agent

Contacts and Locations

Study Contact

David Grosshans
CONTACT
713-563-2300
dgrossha@mdanderson.org

Principal Investigator

David R Grosshans
PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center

Study Locations (Sites)

Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
United States
M D Anderson Cancer Center
Houston, Texas, 77030
United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

  • David R Grosshans, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-04-01
Study Completion Date2027-12-31

Study Record Updates

Study Start Date2019-04-01
Study Completion Date2027-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Anaplastic Ependymoma
  • Ependymoma